Hexalen® (altretamine) Capsules are indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.

About Ovarian Cancer

Ovarian cancer afflicts one in every 67 women and is the leading cause of gynecological cancer-related deaths among American women. The American Cancer Society estimates that there will be approximately 20,180 new cases and 15,310 deaths due to ovarian cancer in 2006.

For more information about Hexalen, please call 1-800-562-5580.